-
Nov 22, 2024 | 
targetedonc.com | Petros Grivas
Petros Grivas, MD, PhD, clinical director of the genitourinary cancers program at University of Washington Medicine and professor at Fred Hutchinson Cancer Center in Seattle, Washington, elaborates on some key unanswered questions on approaches to bladder cancer treatment he discussed with participants at a Case-Based Roundtable event.
-
Nov 21, 2024 | 00404-5?rss=yes&sz=64)
cell.com | Habib Hamidi |Yasin Senbabaoglu |Niha Beig |Juliette Roels |Cyrus Manuel |Xiangnan Guan | +26 more
Keywordsurothelial carcinomatranscriptomicsmolecular heterogeneityPD-L1 blockadepatient stratificationdigital pathologyGet full text accessLog in, subscribe or purchase for full access. References1. Ishida, Y. ∙ Agata, Y. ∙ Shibahara, K. ... Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell deathEMBO J. 1992; 11:3887-38952. Tang, J. ∙ Yu, J.X. ∙ Hubbard-Lucey, V.M. ...
-
Sep 30, 2024 | 
targetedonc.com | Rahul Gosain |Rohit Gosain |Petros Grivas
2 Commerce Drive Cranbury, NJ 08512
-
Sep 30, 2024 | 
targetedonc.com | Rahul Gosain |Rohit Gosain |Petros Grivas
2 Commerce Drive Cranbury, NJ 08512
-
Jul 24, 2024 | 
digitalcommons.library.tmc.edu | Andrea Necchi |Philippe E. Spiess |Roger Li |Petros Grivas
IMPORTANCE: Tumor mutational burden (TMB) is a putative biomarker of efficacy for immune checkpoint inhibitor (ICI) therapies of solid tumors, but not specifically for penile squamous cell carcinoma (PSCC). OBJECTIVE: To characterize biomarker features and ICI therapy outcomes associated with high TMB in PSCC in the routine clinical practice setting.
-
May 17, 2024 | 
urotoday.com | Petros Grivas
Read the Full Video TranscriptAshish Kamat: Hello everyone. Welcome to Uro Today's Bladder Cancer Center of Excellence. I'm Ashish Kamat. I'm here at the AUA 2024 in San Antonio. And it's a pleasure to welcome to the forum a dear friend of the forum, a dear friend of mine, and an expert in bladder cancer, Professor Petros Grivas. Petros, welcome. Petros Grivas: Fantastic to see you. It's great to be at AUA 2024.
-
Jan 29, 2024 | 
bpno.dk | Petros Grivas
januar 2024 The JAVELIN Bladder 100 trial has previously shown a survival benefit with switch maintenance avelumab anti-PD-1 therapy in patients who had a response or stable disease after platinum-based chemotherapy. In this MEDtalk, Dr. Petros Grivas presents the long-term data presented at ASCO GU 2024, which confirmed that the significant prolongation in overall and progression-free survival was achieved with a significant preservation to the patient’s quality of life.
-
Nov 14, 2023 | 
urotoday.com | Petros Grivas
Read the Full Video TranscriptAshish Kamat: Hello, and welcome again to UroToday's Bladder Cancer Center of Excellence. I'm Ashish Kamat, and I have the distinct pleasure of welcoming again, one of our dear friends, and guests, and experts, and everything to do with urothelial cancer, Dr. Petros Grivas. Petros, thank you so much for taking the time. So much happened at ESMO this year, when it came to bladder cancer in general.
-
Sep 11, 2023 | 
targetedonc.com | Petros Grivas
Petros Grivas, MD, PhD, clinical director of the genitourinary cancers program at the University of Washington Medicine and professor in the clinical research division of the Fred Hutch Cancer Center, discusses the design and end points of the phase 2 KEYNOTE-057 trial (NCT02625961).
-
Aug 18, 2023 | 
onclive.com | Petros Grivas
Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington (UW) School of Medicine, clinical director, Genitourinary Cancers Program, UW Medicine, associate professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses several unmet needs within urothelial cancer, as well as how to potentially ameliorate them.
